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Two of the most well-known genetic mechanisms in mammalian cells which control the susceptibility of cells to productive infection by
retroviruses and lentiviruses rely on the cellular Fv1 and Ref1 restriction factors, which act, after viral entry, to prevent productive infection through
their interactions with viral capsid (CA) sequences. While previous studies of Fv1 restriction involving N- and B-tropic murine leukemia viruses
(MLVs) had demonstrated that the identity of a single amino acid residue at CA110 (arginine vs. glutamic acid) determines whether the resulting
virus is N (arg) or B-tropic (glu), analogous studies of dual-tropic MLVs, such as Moloney MLV (Mo-MLV), have shown that additional residues
other than CA110 are also involved in the specification of dual-tropic host range. Here we have further studied the CA determinants of Mo-MLV
host range, with an emphasis on identifying additional CA residues and unique combinations of CA residues which differentially influence the
ability of the resulting virus to infect murine and human cells. First, we show that CA82, a residue previously identified to affect the pattern of Fv1
restriction of different MLV viruses in murine cells, is a particularly strong potentiator of B-tropism in an Mo-MLV background carrying a glutamic
acid residue at CA110 (A110E substitution), and that interestingly, different residues at CA82 lead to distinct patterns of restriction in human but not
in murine cells. We also identify another CA residue, CA214, as a similarly potent potentiator of B-tropism, in the context of the A110E substitution.
While another substitution at CA110, A110R, leads to strong potentiation of N-tropism in murine cells, in the absence of additional mutations, we
found that A110R alone was not sufficient to confer appreciable restriction in Ref1-expressing cells, despite the fact that authentic N-MLV shows
strong restriction in those cells. In conjunction with the A110R substitution, substitutions at CA82, but not at CA214, do lead to significant
restriction in human cells, thus demonstrating a distinction between the interactions between those two determinants of restriction and CA110.
Finally, using cell lines engineered to express the TRIM5αhu gene product, recently identified as the Ref1 restriction factor, and RNAi technology to
knock-down expression of TRIM5αhu in human cells, we directly demonstrate that the unique patterns of restriction observed in human cells with
the different mutants are consistent with a TRIM5αhu-mediated restriction. These studies shed further light on the complex determinants within the
viral CA gene product which control the susceptibility of murine and human cells to retroviral infection.
© 2006 Elsevier Inc. All rights reserved.Keywords: Viral restriction; Host range; Retroviral vectorIntroduction
The species and tissue tropisms of retroviruses and
lentiviruses are traditionally attributed to interactions of the
viral envelope with host cell surface receptors. However, studies
over the past three decades have increasingly demonstrated that
the viral capsid (CA) is also critically involved in the⁎ Corresponding author. Fax: +1 617 4326146.
E-mail address: mulligan@receptor.med.harvard.edu (R.C. Mulligan).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.09.048determination of viral host range of both murine leukemia
viruses (MLVs) (reviewed in Bieniasz, 2003; Goff, 2004) and
lentiviruses (reviewed in Goff, 2004; Towers and Goff, 2003).
This phenomenon has been especially well-documented for
MLVs, in which the capsid (Boone et al., 1983; DesGroseillers
and Jolicoeur, 1983; Ou et al., 1983) interacts with a monogenic
(Odaka, 1969) and dominant (Pincus et al., 1971; Rein et al.,
1976) yet saturable (Duran-Troise et al., 1977) inhibitor called
Fv1, a product of an element within the mouse genome (Best
et al., 1996) that resembles the MuERV-L endogenous retro-
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mechanism, termed Fv1 restriction, two MLV variants were
defined: an N-tropic MLV, which could infect cells derived from
NIH Swiss mice but suffered significant reductions in infections
of BALB/c-derived cells, and a B-tropic MLV, which
manifested the opposite pattern of infection susceptibility
(Hartley et al., 1970). In early studies aimed at defining the
determinants of viral tropism within CA coding sequences,
Kozak and Chakraborti made the critical observation that the
tropism of N-MLV and B-MLV was genetically defined by the
identity of a single amino acid in CA at position 110 (CA110)
(Kozak and Chakraborti, 1996). N-MLV (WN1802N) contains
an arginine at this position and is selectively inhibited by the
product of the Fv1b allele in Balb/c cells, while B-MLV
(WN1802B) possesses a glutamic acid at CA110 and is
selectively restricted by the Fv1n allele in NIH-derived cells.
More recently, it had been shown that similar genetic
mechanisms operate to restrict MLV infection of cells derived
from multiple non-murine species, including cow, pig, monkey,
and human (Towers et al., 2000). In the specific case where
MLVs were pseudotyped with the vesicular stomatitis G protein
(VSV-G) to enable entry into non-murine cell types, N-MLVs
were shown to be selectively restricted relative to B-MLV in
their ability to efficiently transduce a variety of non-murine cell
types. Moreover, the restriction pattern in human cells, as in the
murine-derived cells, was saturable (Towers et al., 2002) and
could be swapped by exchanging the residue at CA110 (Towers
et al., 2000). Similar work with pseudotyped lentiviruses had
demonstrated that they, too, could be restricted at a post-entry
stage in human and primate cells by a dominant host factor
(Besnier et al., 2002; Cowan et al., 2002; Hatziioannou et al.,
2003; Hofmann et al., 1999) which interacted at the level of the
lentiviral capsid (Hatziioannou et al., 2004a; Owens et al., 2003,
2004). The human restriction factor of N-MLV was dubbed
Ref1 (Towers et al., 2000) and the primate inhibitor of lentivirus
infection, Lv1 (Cowan et al., 2002), responsible in large part for
a post-entry restriction phenomenon that differentiates the
tropisms of SIV and HIV as found in nature. TRIM5αhu is now
known to be the host factor responsible for the Ref1 restriction
phenotype in human cells (Hatziioannou et al., 2004b;
Keckesova et al., 2004; Perron et al., 2004; Yap et al., 2004).
Despite the important role of CA110 as a determinant in
retroviral post-entry restriction, changes in this residue alone do
not singularly account for the wide variety of restriction patterns
exhibited by different murine retroviruses (Kozak and Chakra-
borti, 1996; Pryciak and Varmus, 1992). For example, several
dual-tropic MLVs, such as the Rauscher and Friend viruses,
which are able to infect both N and B cells with equal facility,
carry the arginine determinant of N-tropic viruses at CA110
(Jung and Kozak, 2000). Similarly, Moloney murine leukemia
virus (Mo-MLV), another dual-tropic virus, carries an alanine at
CA110, an amino acid that does not specify dual tropism in an
otherwise N- or B-tropic virus background (Jung and Kozak,
2000).
A comparison of the amino acid sequences of CAs from
different MLVs indicates that dual-tropic CAs diverge from
N- and B-tropic CAs at many positions in the capsid codingsequence (Jung and Kozak, 2000, see Table 1). Recognition
of such differences has engendered a series of efforts to
identify specific residues that act either alone or in conjunction
with CA110 to control a specific MLV's pattern of restriction. In
one such effort, Stevens et al. (2004) investigated the role of
CA110 and other CA residues in defining the restriction
characteristics of both dual-tropic (Mo-MLV, Friend) and NR-
tropic viruses (N-like MLVs with a slightly expanded host
range). The study identified a number of CA residues in addition
to CA110 (e.g., CA82, CA92-95, 105, 114, and 117) involved in
the specification of different host ranges, which in some cases
acted in concert with CA110. Based on a model of CA structure,
the authors proposed that those amino acids reside on the
exterior surface of CA, thereby forming a possible surface for
interactions with restriction machinery. In a related type of study,
Lassaux et al. (2005) also characterized CA determinants of
different viral tropisms, focusing predominantly on manipula-
tion of the dual-tropic Friend MLV CA. In addition to defining
additional amino acids which modulated the specification of
host range by CA110 (including CA82), the authors were able to
identify combinations of CA amino acid residues which, when
incorporated into virus, led to patterns of restriction which
revealed distinctions between the Fv1b and Ref1 restriction
systems.
In the studies presented below, we have further investigated
the role of CA110, CA82, and other amino acids present in CA
in the specification of MLV host range, with an emphasis on
identifying additional CA residues and unique combinations of
CA residues which differentially influence the ability of the
resulting virus to infect murine and human cells. The studies
shed further light on the complex role that the viral CA gene
product plays in the ability of retroviruses to infect specific
cells.
Results
Establishment of an experimental system for observing and
quantifying restriction levels and patterns
To readily quantitate the relative infectivity of viruses
constituted with different variant CA sequences on different
cell types, we generated replication-defective MLV-based
retroviral vectors encoding a GFP reporter, using a transient
transfection production system which enabled the facile
generation of viruses carrying variant CA sequences (see
Materials and Methods). Infection efficiency was quantitated
based on GFP expression, as measured by flow cytometry,
and restriction of viral variants was calculated as the
logarithmic reduction of infection levels relative to unrest-
ricted wild-type control viruses. Since classical Fv1 restriction
can be abrogated by the presence of a large excess of viral
particles (Duran-Troise et al., 1977), relatively low multi-
plicities of infection (MOI) were used to quantitate levels of
virus restriction.
In selecting ‘indicator’ cell lines to assay for restriction of
different Mo-MLV mutants, we sought to make use of cells that
had been shown before to reliably restrict either N-MLV or B-
Table 1
Sequence alignment of MLV CA gene products
Modified from Jung and Kozak (2000), Fig. 1. WN1802N and B are N- and B-tropic viruses, respectively; Rauscher, Friend, and Moloney are dual-tropic MLVs.
Bolded residues indicate positions of sequence variation in the amino acid that are present between two or more retroviral capsids. Note that at CA46, 82, 214, and 244,
all three dual-tropic viruses differ from their single-tropic counterparts.
247J.W. Ulm et al. / Virology 363 (2007) 245–255MLV by at least one order of magnitude relative to infection by
wild-type dual-tropic virus. B-MLV was shown to be strongly
and reproducibly restricted in NIH3T3 fibroblasts by up to 2
orders of magnitude relative to N-MLV. N-MLV is restricted in
both BALB/c-derived murine fibroblasts and in multiple non-
murine target cells. However, most commercially available
BALB/c-derived fibroblast lines are difficult to infect and
demonstrate poor restriction of the N-MLV in general
(G. Towers, personal communication and data not shown). In
contrast, one specific BALB fibroblast-derived cell line (BALB
3T1-2) does selectively restrict the N-MLV relative to the
B-MLV, though to a weaker extent at baseline (approximately
½–1 order of magnitude) than the reciprocal selective restriction
of the B-MLV by NIH3T3 fibroblasts. In addition to use of the
BALB 3T1-2 line (gift of G. Towers) as an N-restricting murine
target cell, several additional human-derived cell lines (HT1080
fibrosarcoma cells and RD rhabdomyosarcoma cells), noted by
Towers et al. (2000) to manifest robust restriction of N-tropic
viruses, were also used in the studies.
Analysis of tropisms of Mo-MLV A110R and A110E mutants
As indicated earlier, prior studies had demonstrated that
CA110 alone was not the decisive determinant for the dual-tropic phenotype and that additional residues in the capsid must
be responsible for differentiating dual-tropic MLVs like
Moloney and Friend from N-MLV and B-MLV (Kozak and
Chakraborti, 1996; Pryciak and Varmus, 1992). Although
studies by Stevens et al. (2004) had demonstrated that an
A110R mutation alone in an Mo-MLV background could
precipitate a substantial N-restriction in Mo-MLV, leading to a
reduction in infection of cells expressing the Fv1b restriction
factor, it was unclear whether an A110E mutant would behave
in an analogous fashion and be comparably restricted by Fv1n-
expressing cells. To address this issue, we exchanged the
alanine codon at Mo-MLV CA110 for either the glutamic acid
codon characteristic of B-MLV (A110E), or the arginine found
in N-MLV (A110R). We then examined restriction of the Mo-
MLV A110R and A110E mutants in each of the indicator cell
lines, comparing infection levels with those observed for wild-
type Mo-MLV and the native WN1802N and WN1802B
viruses. As shown in Fig. 1, as expected, virus constituted
with CA carrying the A110R substitution was not restricted in
NIH3T3 cells, and virus carrying the A110E substitution was
not restricted in the BALB 3T1-2 cells or the human lines. Also
as expected, restriction of the A110R mutant was substantial in
the BALB fibroblasts, comparable to that observed with
authentic N-tropic virus. However, in contrast to the case of
Fig. 1. N-like and B-like restriction phenotypes in Mo-MLV CA110 mutants.
Moloney MLV variants were mutated at CA110 alone, from the wild-type
alanine to the equivalent residue in the N-MLV (A110R) or B-MLV (A110E),
and tested in murine and human lines. Values on the y-axis represent logarithms
of the quotient of infectious titers for each mutant (or the N-MLV or B-MLV
controls) divided by corresponding infection levels for wild-type, dual-tropic
Mo-MLV. N=3.
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properties of the A110E carrying virus demonstrated that its
restriction in NIH3T3 cells was modest (less than 5-fold
reduction in titer), suggesting that additional determinants were
necessary in order for the A110E substitution to potentiate
restriction of infection of NIH3T3 cells. Unexpectedly, while N-tropic virus infection was restricted in human HT1080 and RD
human cells, virus carrying the A110R showed minimal
restriction in human cells, despite its restriction of infection of
BALB fibroblasts. These latter results reveal a distinction
between the restriction properties of the murine and human cell
lines with regard to virus possessing N-tropism.
A D82N mutation markedly potentiates Fv1n restriction of
Mo-MLV A110E
The above experiments indicated that while the A110R
substitution alone appears sufficient to engender an N-tropic
restriction in Mo-MLV, the converse does not appear to be true
for A110E. Based on these findings, we next tested other
residues in the capsid for potentiation of a B-like restriction
pattern in the context of virus carrying the A110E substitution.
Specifically, we generated the following substitutions in CA
sequences already carrying the A110E substitution: A4L,
I46T, D82N, K214R, or D244E. Those residues were
identified as potentially important for specifying dual tropism
based on the sequence comparisons of dual-tropic and N- or
B-tropic CA sequences (Table 1). At each position, the codon
specifying the amino acid normally found in B-MLV was
substituted for the corresponding Mo-MLV codon. All of these
substitutions were well-tolerated by the capsid, as infectious
virus could be harvested at high titers from every capsid
mutant, and particles were able to infect control 293T cells as
readily as viruses carrying a wild-type capsid. Thus the
mutations did not result in substantial structural changes to the
capsid that damaged infectivity in general. Equal titers of viral
particles in each case were then used to infect both N-
restricting and B-restricting murine fibroblasts, and Ref1-
expressing human RD and HT1080 cells. The infection
efficiencies of the different viruses observed in NIH3T3
cells are shown in Fig. 2. As shown earlier, the Moloney
A110E mutation alone indeed produced only a modest
decrease in infection levels of B-restricting NIH3T3 murine
fibroblasts (i.e., less than 5-fold reduction in viral titers).
However, in conjunction with changes at either CA82 (D82N)
or CA214 (K214R), a residue not previously implicated as a
determinant of restriction, a significant decrease in titer of
between 50- and 100-fold was observed on NIH3T3 cells.
None of the other double mutants (A110E plus either A4L,
I46T, or D244E) displayed any observable reductions in titer
in infections of the mouse NIH3T3 fibroblasts relative to the
A110E mutant alone. In fact, the A4L/A110E and I46T/
A110E mutant appeared to even modestly reduce sensitivity to
restriction. Most of the A110E variants carrying a second
substitution showed no impaired ability to transduce Ref1-
expressing cell lines (data not shown), consistent with the
known restriction properties of those cells (Fv1b-like pheno-
type). Also, as would be expected, none of the secondary
substitutions affected the restriction properties of A110R-
carrying viruses (since A110R carrying viruses show no
restriction in NIH3T3 cells).
Four other A110E variants carrying additional single
substitutions in other ancillary positions (CA147, 159, 202,
Fig. 3. Infection of N-restricting cell lines with Moloney A110R mutants.
Mo-MLVA110R was assayed for restriction either alone or in conjunction with
an additional mutation at CA82 or CA214, which represent the corresponding
residue found in N-MLV. The variants were tested in human Ref1-expressing
cell lines (HT1080 or RD) and in a murine Fv1b-expressing cell line (BALB
3T1-2) that exhibits a notable but less pronounced N-restriction, with infection
levels measured relative to wild-type Mo-MLV as described before. N=3.
Fig. 2. Relative titers of Moloney CA110 mutants in NIH3T3 cells. NIH3T3 fibroblasts were infected with wild-type Moloney MLVor one of several mutants in an
A110E background, alone or in combination with changes at other positions. A110R mutants are shown for comparison. N=3.
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NIH3T3 cells. N-MLV and B-MLV differ from each other at
CA147 and 159, while at CA202, Mo-MLV and Friend
differ from N and B-MLV, and at CA229, one of the single-
tropic MLVs differs from Mo-MLV. As expected, and in
contrast to CA82 and CA214, substitutions at these ancillary
positions did not significantly potentiate a restriction in Mo-
MLV A110E upon infection of NIH3T3 fibroblasts (data not
shown).
Significantly, changes at residues 82 and 214 alone (i.e.,
in the presence of the wild-type alanine at CA110) had no
impact upon viral tropism. Therefore, CA82 and CA214
appear to act as modulators which potentiate the restriction
directed by CA110.
Mo-MLV A110R is restricted by Fv1b but requires D82N for
Ref1 restriction
As shown earlier in Fig. 1, the Mo-MLV A110R mutant
alone is restricted by an order of magnitude in BALB
fibroblasts, but far less so in human lines manifesting a
potent Ref1 restriction phenotype. Based on the studies
described above which identified both CA82 and CA214 as
potential modulators of restriction at the CA110 locus for the
A110E mutants, we next asked whether those residues might
also function to potentiate a Fv1b or Ref1-mediated restriction
of the A110R variant in murine or human (HT1080 or RD)
cells. For this study, we compared the properties of three
viruses: Mo-MLV A110R alone, A110R/D82N, and A110R/
K214R. As shown in Fig. 3, the restriction of A110R
observed in BALB cells was very significant, and only
negligibly affected by an accompanying D82N mutation. In
contrast, in human cells, the very modest restriction observed
with A110R alone was markedly potentiated by inclusion of
the D82N substitution. Interestingly, Suerunlike the D82N
modification, the K214R mutation had little effect onrestriction in human cells, suggesting a distinction between
the manner in which the two mutations interact with CA110
to control restriction.
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distinctions between patterns of Fv1 and Ref1 restriction
observed in murine and human cells
The existence of dual-tropic murine leukemia virus pheno-
types resistant to both N and B restriction, such as that observed
in the Moloney and Rauscher MLVs, indicates a possible
evolutionary process among MLV capsids that selected for
variants which could escape the intracellular block that prevents
replication. To further explore the nature of the putative
interaction between CA82 and host inhibitory factors, we
generated additional substitutions at CA82 in the background of
the Moloney A110E capsid mutant. The additional CA82
substitutions were chosen so as to represent a diversity of side-
chain structures, including both conservative and non-con-
servative changes from CA82N, so as to evaluate the stringency
of the interaction between this residue and the Fv1n inhibitory
machinery. The substitutions that were tested included: D82R,
D82K, D82E, D82G, and D82Q. The results of experiments
with the A110E CA82 mutants are displayed in Fig. 4.
Surprisingly, all of the CA82 substitutions, including the
conservative mutation D82E, found naturally in the FriendFig. 4. Restriction of Moloney CA82 side-chain mutants. Mutants at CA82 in the
N-restricting (HT1080) targets at low MOI. N=3.and Rauscher MLV CAs, significantly potentiated the restric-
tion of the parental A110E virus in murine cells. Apparently, in
the context of Mo-MLV, even a conservative substitution
abrogates the resulting virus of its dual tropism in murine cells;
only the aspartate at CA82 appears to enable the capsid to
escape inhibition by the Fv1 restriction machinery. Interest-
ingly, however, in human cells, the different mutants showed
significantly more variations in their capacity for infection,
suggesting again a distinction between the restriction mechan-
isms operating in murine and human cells.
Patterns of restriction of infection of human cells by different
CA mutants are controlled by TRIM5αhu
Given the distinctions observed between the restriction
properties of a number of the mutant Mo-MLV viruses observed
in murine vs. human cell lines, we next directly examined
whether infection of human cells by the different viruses was
indeed governed by Ref1/TRIM5αhu. In a first series of studies,
selected Mo-MLV mutants were tested for infection on HT1080
(Ref1+) cells previously treated either with siRNA specific for
TRIM5αhu mRNA, or a non-specific siRNA reagent, using aMo-MLV A110E background were used to infect B-restricting (NIH3T3) and
Fig. 5. Patterns of restriction of infection of human cells by different CA mutants are controlled by TRIM5αhu. (A) RNAi-mediated suppression of TRIM5αhu-based
Ref1 restriction of Mo-MLVA110R mutants. HT1080 human fibrosarcoma cells were pre-treated with either a random control siRNA (−) or an siRNA specific for
TRIM5αhu mRNA (+), then assayed for retroviral infection by different GFP-expressing CA mutants as indicated. N=3. (B) Assay of restriction in cells engineered to
express TRIM5αhu. “LPCX” represents the control 293T cell line stably transduced with the empty pLPCX vector and “TRIM5αhu stably transduced” represents cells
engineered to express TRIM5αhu. Numbers within the boxes represent percentages of GFP-positive cells within the total cell population. N=3. A representative
experiment is illustrated.
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shown in Fig. 5A, RNAi knock-down of TRIM5αhu led to
a dramatically higher infection of HT1080 cells by authentic
NQMLV, consistent with the known control of N-MLV by Ref-1
(Stremlau et al., 2004). Infection of HT1080 cells by B-MLV, or
either the A110E, A110R, or A110R/K214R mutants of Mo-
MLV, which do not show significant restriction in HT1080 cells,
was not appreciably affected by siRNA-mediated inhibition of
TRIM5αhu. Importantly, however, the strong restriction of
infection observed in the case of the A110R/D82N mutant of
Mo-MLV was significantly relieved by siRNA treatment, in a
manner comparable to that observed in the case of N-MLV
infection of siRNA-treated cells.
In a second series of studies, human Ref1-negative 293T
cells were engineered to express TRIM5αhu via retroviral vector
transduction, and the resulting cells were used to assess the
Ref1-mediated restriction of several CA mutants. The efficiency
of infection of TRIM5αhu-expressing cells was determined by
FACS analysis of infected cells, and compared to the efficiency
of infection of 293T cells transduced by an ‘empty’ vector
encoding no transgene. As shown in Fig. 5B, as expected, B-
MLVand the A110E/D82N mutant, which showed no apparent
restriction in HT1080 cells, infected both mock-transduced
(“LPCX control”) and TRIM5αhu-expressing 293T cells at
equal efficiencies. In contrast, N-MLV, subject to Ref1
restriction, infected TRIM5αhu-expressing cells at a dramati-
cally lower (approximately 40×) efficiency than what was
achieved on mock-transduced cells. Interestingly, the relative
ability of the different mutant viruses to transduce TRIM5αhu-
expressing vs. mock-transduced cells mirrored the ability of the
same viruses to infect HT1080 cells. For example, A110R/
D82N, which of all the mutants was the most significantly
restricted in the ability to infect HT1080 cells, also was the least
able of the mutants to infect TRIM5αhu-expressing cells (i.e.,
1.66% infected TRIM5αhu-expressing cells vs. 14.3% infected
mock-transduced cells). The A110R and A110R/K214R
viruses, which manifest an N-tropic phenotype on murine
cells, but are restricted only slightly in their ability to infect
HT1080 cells, infected TRIM5αhu-expressing cells at approxi-
mately half the efficiency of infection that was observed in
mock-transduced cells. A110E/D82N, which exhibits a strong
B-tropic phenotype in murine cells, appeared to infect
TRIM5αhu-expressing cells as least as well if not better than
mock-transduced cells. Along with the RNAi data, these studies
strongly suggest that TRIM5αhu is directly responsible for the
restriction that has been noted for the Mo-MLV variants.
Discussion
In the work reported here, we have further characterized
determinants for viral host range in the Mo-MLV capsid. Our
studies extend the findings of previous studies of the CA
determinants of Mo-MLV host range in several significant
ways. First, while others (Stevens et al., 2004) had shown that
infection by virus carrying the A110R substitution alone is
significantly restricted in BALB cells (expressing Fv1b), our
studies indicate that viruses carrying an A110E mutation do notshow the analogous restriction in NIH3T3 fibroblasts (Fv1n); an
additional modification of Mo-MLV CA is required to elicit a
significant restriction in those cells. In addition to identifying
CA82 as a strong potentiator of B-tropism in A110E carrying
viruses, our studies reveal CA214 as a previously undescribed
strong potentiator of B-tropism. We show that while CA82 does
not appreciably affect the already strong N-tropic phenotype
exhibited by A110R, as revealed in murine cells, it does play an
important role in the restriction of the mutant viruses in Ref1-
expressing human cells, a property that CA214 does not
possess. These results suggest that CA82 and CA214 interact
with CA110 in distinct ways to engender specific restriction
patterns, and also extend previous studies which had defined
distinctions between Fv and Ref1-mediated restriction (Lassaux
et al., 2005; Yap et al., 2004). Interestingly, our studies of Mo-
MLVA110E mutants carrying different amino acid substitutions
at CA82 demonstrated that virtually all residues tested
(including conservative changes relative to the native aspartate)
led to consistently potentiated restriction in murine cells.
Studies of those different CA82 substitutions in human cells,
however, revealed significant differences in restriction, and
therefore, again reveal differences between the restriction
pathways operating in murine and human cells.
The precise mechanism whereby changes in CA82
influence restriction by Fv1 and TRIM5αhu remains to be
determined. Taylor and colleagues recently reported the
structure of the N-MLV capsid N-terminal domain, which
crystallized as a hexamer thought to represent the native
assembly unit of the retroviral capsid (Mortuza et al., 2004).
Of interest, CA82 and CA110 are proximal on the N-MLV
capsid surface and potentially accessible to restriction factors.
Recent work (Perron et al., 2006) has suggested that determi-
nants within human TRIM5α for potent N-MLV restriction
reside in acidic residues in surface-exposed loops of the B30.2/
SPRY domain, which is thought to contact the retroviral capsid.
These TRIM5α acidic residues conceivably interact with basic
residues on the capsid surface. The presence of an aspartic acid at
CA82 may allow the formation of a salt bridge with arginine at
CA110, reducing the efficiency of interaction with the acidic
TRIM5α surface and allowing escape from restriction. When
CA110 is glutamic acid, an arginine residue at CA82 may
provide a positive charge on the exposed capsid surface
conducive to TRIM5α interaction and restriction. Further
studies will be required to test these models and to understand
the influence of CA214, in the C-terminal capsid domain, on Fv1
restriction.
In addition to shedding further light on the fundamental
genetic mechanisms of retroviral restriction, studies such as
those presented above may, in the future, provide a novel
avenue for manipulating viral vector host range. Our studies
demonstrate that certain manipulations of CA residues led to
the generation of viruses possessing novel restriction patterns
distinct from standard viruses commonly used in the
laboratory. These findings extend the seminal studies of
Kozak and Chakraborti (1996) which previously documented
the ability to generate viruses possessing novel host ranges
via simple modifications of the retroviral CA. The design of
253J.W. Ulm et al. / Virology 363 (2007) 245–255viral vectors which possess novel expanded or restricted host
ranges by virtue of modifications of CA sequences could
have utility in both experimental and clinical settings of gene
transfer.
Materials and methods
Cell lines
293T human embryonic kidney cells (American Type
Culture Collection) were utilized for virus production and as
one of the cellular targets for generated viruses. Murine NIH3T3
embryonic fibroblasts (ATCC) were used as the standard B-
MLV restricting (N-permissive) murine cell line, and BALB
3T1-2 fibroblasts as the N-restricting line. For studies of Ref1
restriction in human targets, we utilized two human mesench-
ymal lines, noted by Towers et al. (2000) to selectively restrict
the N-MLV 2–3 logs greater than the B counterpart: HT1080
fibrosarcoma and RD rhabdomyosarcoma cells (ATCC), the
latter closely related and perhaps ancestral to the TE671
mesenchymal cells (Towers et al., 2000).
Lines were maintained as monolayers in 10- or 15-cm dishes
at 37 °C, 5% CO2. Media preparations were as follows (all
reagents other than minimal media obtained from GIBCO).
293T and BALB 3T1-2: Dulbecco's modified Eagle's medium
(DMEM) high glucose, 10% inactivated fetal serum (IFS), 1%
penicillin/streptomycin, 2 mM L-glu. NIH3T3: DMEM high
glucose, 10% calf serum, 1% pen/strep. HT1080: Eagle's
minimal essential medium (EMEM), modified (ATCC 30-
2003), 10% IFS, 1% pen/strep, 2 mM LQglu. RD: DMEM,
modified (ATCC 30-2002), 10% IFS, 1% pen/strep, 2 mM L-glu.
Plasmid constructs
Viral particles for each experiment were generated via
tripartite transfection of packaging and vector plasmids into
293T cells, as described below. To generate virus possessing
different CA variants, our standard expression construct
encoding MLV gag-pol, termed pCG-gag-pol, which makes
use of a CMV promoter, a β-globin intron, and a β-globin
polyadenylation signal for expression of the viral sequences,
was modified to encode the desired mutations.
The wild-type N-MLV gag-pol (WN1802N) and wild-type
B-MLV gag-pol (WN1802B) sequences were originally
provided to us as a gift from J. Stoye as pCIG-N and pCIGQB.
In the case of those constructs, site-directed mutagenesis
(QuikChange Kit, Stratagene) was used to introduce a NotI
site immediately downstream of the N- and B-MLV stop
codons; an EcoRI-NotI fragment containing the gag-pol from
pCIG-N and pCIG-B was then isolated and cloned into the pCG
construct just downstream of the CMV promoter and β-globin
intron present in pCG, to generate pCG-CIGN and pCG-CIGB.
Virus production and infection of target cells
The VSV-G expression construct, wild-type retroviral gag-
pol or capsid mutant construct, and GFP-expressing retroviralvector were transfected together into 6-cm dishes containing 5–
6×106 293T cells using standard calcium phosphate protocols
and solutions produced either in-house or commercially
supplied (Promega Profection™ system). Plasmids were
transfected at a standard ratio of 3 μg VSV-G: 3 μg gag-pol:
4 μg GFP vector in the presence of standard 293 media. At 10–
12 h post-transfection, media containing the transfected
constructs was removed, and cells were washed 2× with fresh
media to remove residual plasmid DNA from the dish; 2 ml
fresh media was then added. At 24 h after transfection,
supernatant containing viral particles was isolated and fresh
media again introduced, a procedure repeated at 36- and 48-h
timepoints. Transfected cells were checked at 24 and 48 h to
ensure that all cells were expressing GFP and at similar levels
from dish to dish; if transfection was uneven or nonexistent in
any of the plates, the experiment was aborted and initiated again
using fresh stocks.
Viral supernatants were passed through 0.45-μm-diameter
filters to remove residual cell debris, then used to infect 293T
cells in 6-well dishes. These cells were observed (Towers et al.,
2000) to be a “neutral” line without N or B restriction, analogous
to the Mus dunni line, and each of our viral mutants was indeed
unrestricted within them; they were therefore used for particle
titering purposes according to standard practices. Infections
were performed in the presence of 5 μg/ml polybrene at three
dilutions of virus to establish titers and ensure that viral particles
per unit volume supernatant did not vary significantly from
sample to sample. A dot blot using a probe directed against viral
RNA was also performed early in the experiments, to establish
that equal titers on 293T infections also showed equal titers on
the dot blot (data not shown). Thus the numbers of particles for
each viral variant within a given experiment were normalized to
ensure equal counts in each case, and multiplicities of infection
(MOIs) used across experiments reported here are defined via
titers established upon infection of 293T cells. All of the MLV
capsid mutations were well tolerated and did not affect the
viruses' capacity to infect the control 293T cells. Thus the
variable infection levels that we encountered in N-restricting or
B-restricting cell types could be traced to a selective inhibition in
those lines that depended crucially on the mutant retroviral
phenotype.
Quantitation of restriction
To test for restriction, equal numbers of particles were used to
infect a variety of target cells in 6-well or 24-well dishes (with
swirling of dish) at varying dilutions and generally at low
multiplicities of infection (≤0.5). Supernatant was removed 10 h
after infection and replaced with fresh media, and a subsequent
medium change was made again at 36 h post-infection.
Restriction assays of wild-type N- and B-tropic MLVs, as
well as the dual-tropic Mo-MLV, were conducted initially in
each cell line to measure baseline restriction levels. Trial
experiments of each capsid variant were then undertaken at
multiple dilutions to ensure that MOIs of mutants and wild-type
viruses were within a linear range. Logarithms of mutant
infection divided by wild-type infection levels, in triplicate,
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by each mutant, helping to identify large decreases and thus
substantial levels of inhibition.
At 60 h following infection, media was removed from test
cells, which were subsequently washed carefully 2× with PBS,
then removed from plates following brief treatment with
trypsin–EDTA (0.05%, GIBCO). Cells in trypsin were then
added to an excess volume of MACS buffer (PBS+0.5% BSA
Fraction V, Sigma) in 5 ml Falcon round-bottom polystyrene
tubes and spun down at 1500 rpm in a Sorvall table-top
centrifuge (Dupont) to pellet isolated cells. The pellet was then
resuspended in MACS buffer plus 2 μg/ml propidium iodide
(PI, Molecular Probes) prior to flow cytometric analysis.
Cells were analyzed for expression of the reporter using a
FACSCalibur (Becton Dickinson). Within each cell group, the
live cell population (low PI) containing the proper size and
shape as determined by scatter characteristics, was gated and
compared against a mock-infected negative control for each test
sample. Cells were plotted as PE fluorescence vs. GFP on the
xQaxis and compensated as necessary. FACS data were
subsequently analyzed with appropriate software (FlowJo™)
and percentages of GFP-positive cells in each sample recorded.
RNAi assays
HT1080 cells were treated with siRNA sequences directed to
TRIM5αhu essentially as described by Stremlau et al. (2004). In
brief, the following small interfering RNA (siRNA) 21-mer
oligonucleotides were utilized: siRNA #3 (Dharmacon RNAi
Technologies), designed against a common region in the
TRIM5α protein (human and rhesus monkey alleles) (5′-
GCCUUACGAAGUCUGAAACdTdT-3′), and a second
siRNA containing randomly generated sequence (5′-AUGAAC-
GUGAAUUGCUCAAUU-3′) was employed as a negative
control. 120 nmol of each siRNA was mixed with 10 μl
Oligofectamine™ (Invitrogen) in Opti-Mem minimal serum-
free media (Gibco, Life Technologies) and added to serum-
starved HT1080 cells. At 4 h, 500 μl DMEM with 3× serum
concentration was added to each well, followed by replacement
with standard HT1080 media 24 h later (Day 3). On Day 4,
HT1080 cells were seeded for infection, with each well of the 6-
well dish furnishing sufficient cells for three wells of a 24-well
plate. Direct verification of RNAi efficacy against the TRIM5α
target was difficult, since available antibodies to the TRIM5α
protein were of limited avidity and Western blot quantitation
therefore not very revealing (Stremlau et al., 2004).We therefore
gauged RNAi functionality based on the capacity of siRNA #3 to
relieve the restriction on the N-MLV control in HT1080 cells, as
previously reported (Perron et al., 2004).
Measurement of restriction in TRIM5α-stable cell lines
293T cells were engineered to express TRIM5αhu as
described by Perron et al. (2004). Briefly, a hemagglutinin
(HA)-tagged cDNA of TRIM5αhu was introduced downstream
of the CMV promoter in the pLPCX vector (Clontech), which
contains a puromycin resistance cassette under control of theviral LTR. This pLPCX-derived vector was then co-transfected
into 293T cells along with gag-pol and VSV-G-expressing
constructs to produce viral particles which were isolated and
then used to infect a separate batch of 293T cells. Clonal
populations of TRIM5αhu-expressing cells were subsequently
selected in 1 μg/ml puromycin, and used in infectious virus
assays. A second 293T cell line transduced by a pLPCX vector
carrying no transgene insert was used as a control. Both cell
lines were maintained in standard 293T media in the presence of
puromycin to ensure retention of the transgene.
Both TRIM5αhu-expressing and pLPCX-transduced 293T
cells were infected in 24-well dishes by GFP-expressing virus in
the presence of polybrene as detailed above. To ensure
uniformity from well to well, the total volume of viral
supernatant and media was adjusted to 1 ml, and then
puromycin added to reach a concentration of 1 μg/ml in each
well. Supernatant was removed at 10 h following infection and
fresh puromycin-containing 293T medium added back. Media
was again replaced at 36 h and cells checked to ensure no
significant loss from puromycin toxicity. At 60 h, cells were
trypsinized and harvested for fluorometric analysis.
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